Company Directory / biotech/health
PrivateFor profitbiotech/healthAntwerpen, Belgium
AgomAb Therapeutics
AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.
- Founded
- 2017 9 years ago
- Staff
- 11-50 band, as listed
- Followers
- - on LinkedIn
- Funding
- $237M as listed, currency not stated
Set against six million companies
Size
11-50 people: larger than 33% of companies with a size listed
Age
9 years old.
Reach
Website ranked #5,452,783 in the world for traffic, about 1k visits a month.
What it does
BiotechnologyHealth CareTherapeutics
Funding, as listed
$237M currency not stated
- Rounds4
- LatestSeries c, Oct 2023
- Investors16, 5 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about AgomAb Therapeutics, field by field. Contact details are held but never shown.
The company
- Name
- AgomAb Therapeutics
- Type
- For profit
- Status
- Private
- Founded
- 2017
- Founders
- Federica Linty, Hans De Haard, Manuela Cazzanti, Michael Saunders, Virginia Morello
- Industry
- biotech/health
- Categories
- Biotechnology, Health Care, Therapeutics
Where
- City
- Antwerpen
- Country
- Belgium
- Markets
- European Union (EU), Europe, Middle East, and Africa (EMEA)
Size and reach
- Staff band
- 11-50
- Web traffic rank
- #5,452,783
- Monthly web visits
- 1,360
Funding, as listed
- Total
- 236,963,512 (currency not stated)
- Rounds
- 4
- Latest round
- Series c
- Latest round date
- Oct 2023
- Investors
- 16
- Lead investors
- 5
- Listing status
- private
Corporate family
- Acquisitions made
- 1
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
AgomAb Therapeutics may be growing as it has recently secured significant funding, with a $100 million investment in its Series C funding round. This capital infusion is intended to advance the company's ALK5 inhibitor through a phase 2 trial for Crohn's disease, indicating progress in its drug development pipeline. Additionally, the company has been recognized for its innovative approach to combating fibrosis, which could suggest a strengthening of its market position. The appointment of new members to its board of directors and the hiring of a Chief Development Officer also suggest an expansion of its leadership team to support its growth trajectory.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
biotech/health in Belgium.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 36,920 companies in Belgium and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.